ASCO GU 2023 - Results from #40

Viewing 41-60 of 190 articles

ASCO GU 2023: Sequential Intravesical Gemcitabine and Docetaxel Versus Bacillus Calmette-Guérin for the Treatment of High-Risk, Treatment-Naïve, Non-Muscle Invasive Bladder Cancer

ASCO GU 2023: Radical Nephroureterectomy Followed by Adjuvant Chemotherapy Versus Observation in Early-Stage Upper Urinary Tract Cancers with Variant Histology

ASCO GU 2023: Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-057 Trial

ASCO GU 2023: EV-104: Phase 1 Study of Intravesical Enfortumab Vedotin for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

ASCO GU 2023: 18F-DCFPyL PET in First Biochemical Recurrence and Initial Staging: Concordance with Conventional Imaging

ASCO GU 2023: Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Patients with Clinically Node-Positive Upper Tract Urothelial Cancer (UTUC) Who Underwent Radical Nephroureterectomy

ASCO GU 2023: Radium-223 for mCRPC, a Real-World Experience Study from 7 Galician Medical Centers

ASCO GU 2023: Patterns of Failure After Radiotherapy in Patients with Prostate Cancer Re-Staged with 18F-DCFPyL PSMA-PET: A Regional Cohort Analysis

ASCO GU 2023: Lutetium-177 PSMA Radioligand Therapy for mCRPC in Germany: Population-Based Data with Multicenter Validation from 2016 to 2020

ASCO GU 2023: Predictive and Prognostic Potential of Pretreatment 68Ga-PSMA PET Tumor Heterogeneity Index in Patients with mCRPC

ASCO GU 2023: IMvigor130 and the Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma

ASCO GU 2023: Pembrolizumab Monotherapy for Patients with High-Risk Non–muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette–Guérin (BCG): Results from Cohort B of the Phase 2 KEYNOTE-057 Trial

ASCO GU 2023: Addressing Health Equity by Expanding Trial Eligibility Criteria in Urothelial Carcinoma

ASCO GU 2023: Extended Follow-up Results from the CheckMate 274 Trial

ASCO GU 2023: The Impact of the Financial Cost: How Much Is It Costing Our Patients With Bladder Cancer?

ASCO GU 2023: Gender Specific Differences in Health-Related Quality of Life for Patients with Bladder Cancer Following Radical Cystectomy

ASCO GU 2023: Atezolizumab + Platinum/gemcitabine vs Placebo + Platinum/Gemcitabine for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Final OS from the Randomized Phase 3 IMvigor130 Study

ASCO GU 2023: Final OS Analysis of Atezolizumab Monotherapy vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Carcinoma from the Phase 3 IMvigor130 Study

ASCO GU 2023: It's Time to Talk About Value-Based Care and Time Toxicity With Our Patients

ASCO GU 2023: Socioeconomic Vulnerability and the Risk of Genitourinary Cancer Mortality Among United States Counties

1
2
3
4
5
6
7
8
9
10